Stivarga 40 mg Alternative – Regocent (Regorafenib) 40 mg Tablet | Incepta Pharmaceuticals
Regocent 40 mg (Regorafenib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Stivarga (Bayer).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Product Overview
Regocent 40 mg is listed in the supplied Lucent product catalogue. Its proposed active ingredient is Regorafenib, in tablet form. Manufacturer-specific composition is pending verification; do not rely on this listing for dispensing.
Regocent vs Stivarga – Reference Brand Comparison
Stivarga is a recognized reference brand associated with Bayer. Regocent is listed on the supplied Lucent products price sheet, attributed by the customer to Incepta Pharmaceuticals Ltd. Matching an active ingredient does not demonstrate bioequivalence, regulatory approval or permission to substitute.
Composition and Product Details
- Listed brand: Regocent
- Generic: Regorafenib (pending manufacturer confirmation)
- Strength: 40 mg
- Dosage form: Tablet
- Catalogue pack: 10 tablets
- Attributed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Therapeutic Uses and Indications
Regorafenib is used in selected previously treated colorectal cancers, gastrointestinal stromal tumors and liver cancers. These are generic-medicine contexts, not independently confirmed approvals for this particular branded presentation. Exact eligible conditions, biomarkers and combination therapies must be confirmed from the local authorized label.
Mechanism of Action
Regorafenib inhibits several kinases involved in tumor growth and angiogenesis. Individual treatment response depends on the disease, formulation, dosing and patient factors.
Dosage and Administration
The stated 40 mg refers to the strength of the supplied product, not a recommended daily or treatment dose. Administration schedules, preparation, food instructions and monitoring depend on the approved indication and formulation. Use only the dose and schedule prescribed by a qualified clinician. Never change strength or substitute a brand without medical advice.
Contraindications
Contraindications can include hypersensitivity and other medicine-specific conditions. Review the current prescribing information for all absolute restrictions, including relevant pregnancy-related contraindications.
Warnings and Precautions
Potential serious risks and monitoring requirements vary by medicine. Discuss infections, cardiovascular disease, liver and kidney function, other medications and pregnancy plans with the specialist. The official product leaflet determines the required safety monitoring.
Possible Side Effects
Adverse reactions may involve gastrointestinal symptoms, fatigue, laboratory abnormalities, infections or organ-specific toxicity, depending on the active ingredient. The full medicine-specific adverse effect profile, frequency and emergency warning signs must be reviewed in the authorized prescribing information.
Drug Interactions
Prescription drugs, nonprescription medicines, herbal products and some foods may interact with Regorafenib. A pharmacist or specialist should review all current medicines before treatment.
Pregnancy and Breastfeeding
Some treatments can cause fetal harm or require interruption of breastfeeding. Consult the product-specific label and treating specialist for pregnancy testing, contraception and breastfeeding guidance.
Storage and Handling
Follow the temperature, light protection, cold-chain and handling requirements printed on the actual pack. Do not assume storage conditions from another brand or formulation.
Why Is Regocent Listed as an Alternative to Stivarga?
The comparison is provided for product discovery by active ingredient and reference brand. It does not establish pharmaceutical or therapeutic equivalence, biosimilarity, interchangeability or authorization in any country.
Manufacturer Information
Listed manufacturer: Incepta Pharmaceuticals Ltd., Bangladesh
Reference brand: Stivarga
Reference company: Bayer
Generic: Regorafenib
Strength: 40 mg
Pack: 10 tablets
Frequently Asked Questions
What does Regocent contain?
Regorafenib 40 mg, subject to confirmation against the official brand-specific label.
Is Regocent the same as Stivarga?
No automatic equivalence or interchangeability can be inferred from the generic ingredient alone.
Can I use another strength instead?
Only when an authorized clinician specifically directs it.
Is a prescription required?
Yes. Appropriate prescription and specialist supervision are required.
Important Medical Disclaimer
Educational product identification only. Clinical information and product availability require verification against official labeling and destination-country regulatory requirements. No purchase or treatment decision should be based on this page alone.
| Generic Name | Regorafenib |
|---|---|
| Strength | 40 mg |
| Manufacturer | Incepta Pharmaceuticals Ltd. |
| Pack Size | 10 tablets |
Related products
Avastin 100 mg Alternative – Bevixa (Bevacizumab) 100 mg IV infusion | Incepta Pharmaceuticals
Bevixa 100 mg (Bevacizumab) IV infusion is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Avastin (Roche).
Pack: 1 vial. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Avastin 400 mg Alternative – Bevixa (Bevacizumab) 400 mg IV infusion | Incepta Pharmaceuticals
Bevixa 400 mg (Bevacizumab) IV infusion is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Avastin (Roche).
Pack: 1 vial. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Gleevec / Glivec 100 mg Alternative – Imaxen (Imatinib) 100 mg Tablet | Everest Pharmaceuticals
Imaxen 100 mg (Imatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Gleevec / Glivec (Novartis). It belongs to the BCR-ABL/KIT/PDGFR kinase inhibitor class and is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings.
Active ingredient: Imatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lonsurf 15 mg / 6.14 mg Alternative – Trifluxen (Trifluridine 15 mg + Tipiracil 6.14 mg) 15 mg / 6.14 mg Tablet | Everest Pharmaceuticals
Trifluxen 15 mg / 6.14 mg (Trifluridine 15 mg + Tipiracil 6.14 mg) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lonsurf (Taiho Oncology). It belongs to the trifluridine/tipiracil combination class and is used in selected previously treated metastatic colorectal cancer and other authorized settings.
Active ingredient: Trifluridine 15 mg + Tipiracil 6.14 mg
Strength: 15 mg / 6.14 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Stivarga 40 mg Alternative – Regora (Regorafenib) 40 mg Tablet | Beacon Pharmaceuticals
Xeloda 500 mg Alternative – Capixet (Capecitabine) 500 mg Tablet | Everest Pharmaceuticals
Capixet 500 mg (Capecitabine) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xeloda (Roche). It belongs to the oral fluoropyrimidine chemotherapy class and is used in selected colorectal, breast and other cancer regimens.
Active ingredient: Capecitabine
Strength: 500 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.